Compare DTF & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DTF | CYPH |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.5M | 73.4M |
| IPO Year | 1995 | N/A |
| Metric | DTF | CYPH |
|---|---|---|
| Price | $11.46 | $0.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.21 | $0.49 |
| 52 Week High | $11.61 | $3.70 |
| Indicator | DTF | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 38.88 |
| Support Level | $11.37 | $0.58 |
| Resistance Level | $11.48 | $0.79 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 18.37 | 8.51 |
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.